---
title: "RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296822172.md"
description: "RemeGen reported a 435.74% year-on-year surge in interim revenue to RMB5,850.2 million for H1 2026, driven by strong sales of telitacicept and disitamab vedotin, plus license income from AbbVie. The company secured new regulatory approvals for telitacicept indications and breakthrough therapy status for disitamab vedotin in gastric and bladder cancer. Analysts maintain a Buy rating with a HK$129 price target."
datetime: "2026-08-24T15:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296822172.md)
  - [en](https://longbridge.com/en/news/296822172.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296822172.md)
generator: "portal-rs"
---

# RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones

RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an update.

RemeGen Co., Ltd. reported a sharp rise in interim revenue to RMB5,850.2 million for the six months ended June 30, 2026, a 435.74% increase year-on-year driven by robust sales of its commercial-stage drugs telitacicept and disitamab vedotin, as well as substantial technology license income from an exclusive RC148 deal with AbbVie Inc. This performance reflects accelerating commercialization and growing global partnerships, supported by multiple Phase III milestones and new regulatory approvals in China for telitacicept indications and breakthrough therapy status for disitamab vedotin in advanced gastric and bladder cancer settings, strengthening the company’s position in autoimmune and oncology therapeutics.

Telitacicept advanced with first patient dosing in several Phase III trials in China, high-profile publication of IgA nephropathy data, and new marketing approvals and conditional approvals for Sjögren’s syndrome and IgA nephropathy, including a pre-filled syringe formulation. Disitamab vedotin gained breakthrough therapy designation from China’s CDE for a first-line HER2-high advanced gastric cancer regimen, initiated a Phase III trial in this indication, and presented updated Phase II data in HER2-expressing muscle-invasive bladder cancer at a major international oncology meeting, enhancing its clinical and regulatory momentum.

The most recent analyst rating on (HK:9995) stock is a Buy  
 with a HK$129.00 price target.  
 To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock,  
 see the HK:9995 Stock Forecast page. 

**More about RemeGen Co. Ltd. Class H**

RemeGen Co., Ltd. is a PRC-based biopharmaceutical company focused on the development and commercialization of innovative biologic therapies for autoimmune diseases and oncology. Its key marketed products include telitacicept for autoimmune indications and disitamab vedotin for tumor treatment, with an expanding pipeline targeting conditions such as IgA nephropathy, Sjögren’s syndrome, and HER2-expressing cancers.

**Average Trading Volume:** 4,892,544

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$68.16B

For an in-depth examination of 9995 stock, go to TipRanks’ Overview page.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [RemeGen files board, board committee member list with disclosure responsibilities](https://longbridge.com/en/news/296803857.md)
- [Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?](https://longbridge.com/en/news/296816441.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal](https://longbridge.com/en/news/294974949.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**